NBIX News and Press, Neurocrine Biosciences Inc. From 11/18/21

BMO has initiated shares of Neurocrine Biosciences (NASDAQ:NBIX) with an underperform rating, saying that sales of the company's tardive dyskinesia drug Ingrezza (valbenazine) are unlikely to exceed $2B. Analyst Evan Seigerman writes that pricing pressure on the drug is likely to increase due...

Sharp down days are when to look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and th...

Shares of biopharma Neurocrine Biosciences (NASDAQ: NBIX) were down 9.8% in Tuesday's late trading following a disappointing third-quarter report. For the three-month stretch ending in September, Neurocrine turned $296 million in revenue into an operating profit of $0.64 per...

Neurocrine Biosciences (NBIX -10.3%) has recorded the biggest intraday loss since Nov. 2020, even as Wall Street stands behind the neuroscience-focused biotech after lower-than-expected financials posted by the company for Q3 2021. Hurt by a delayed return to pre-pandemic momentum, Tardi...

Neurocrine Biosciences, Inc. (NBIX) Q3 2021 Earnings Conference Call November 1, 2021 4:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer and Director Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial ...

Image source: The Motley Fool. Neurocrine Biosciences, Inc (NASDAQ: NBIX) Q3 2021 Earnings Call Nov 1, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcr...

Although Neurocrine Biosciences (NASDAQ:NBIX) swung to a Q3 2021 non-GAAP net income of $62.6M from a loss of $16.9M in the prior-year period, the company missed Street estimates on both EPS and revenue. Shares are down ~6% in after-hours trading. Revenue in the quarter increased ~1...

Neurocrine Biosciences (NASDAQ:NBIX): Q3 Non-GAAP EPS of $0.64 misses by $0.16; GAAP EPS of $0.23 misses by $0.34. Revenue of $296M (+14.5% Y/Y) misses by $1.49M. Press Release Net product sales for the third quarter of 2021 were $287 million and $285 million on an inventory adjusted basis Re...

Neurocrine Biosciences Reports Third Quarter 2021 Financial Results INGREZZA® (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions PR Newswire SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neuro...

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021 PR Newswire SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorde...